Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

49,272 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Targeting hydrogen sulfide as a promising therapeutic strategy for atherosclerosis.
Xu S, Liu Z, Liu P. Xu S, et al. Among authors: liu z, liu p. Int J Cardiol. 2014 Mar 15;172(2):313-7. doi: 10.1016/j.ijcard.2014.01.068. Epub 2014 Jan 24. Int J Cardiol. 2014. PMID: 24491853 Review.
Deletion of sirtuin 6 accelerates endothelial dysfunction and atherosclerosis in apolipoprotein E-deficient mice.
Liu Z, Wang J, Huang X, Li Z, Liu P. Liu Z, et al. Among authors: liu p. Transl Res. 2016 Jun;172:18-29.e2. doi: 10.1016/j.trsl.2016.02.005. Epub 2016 Feb 11. Transl Res. 2016. PMID: 26924042
Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1).
Liu Z, Xu S, Huang X, Wang J, Gao S, Li H, Zhou C, Ye J, Chen S, Jin ZG, Liu P. Liu Z, et al. Among authors: liu p. Br J Pharmacol. 2015 Dec;172(23):5661-75. doi: 10.1111/bph.13068. Epub 2015 Feb 27. Br J Pharmacol. 2015. PMID: 25572313 Free PMC article.
RIP140 triggers foam-cell formation by repressing ABCA1/G1 expression and cholesterol efflux via liver X receptor.
He Y, Zhang L, Li Z, Gao H, Yue Z, Liu Z, Liu X, Feng X, Liu P. He Y, et al. Among authors: liu z, liu x, liu p. FEBS Lett. 2015 Feb 13;589(4):455-60. doi: 10.1016/j.febslet.2015.01.001. Epub 2015 Jan 20. FEBS Lett. 2015. PMID: 25616132
Sirtuin-6 inhibits cardiac fibroblasts differentiation into myofibroblasts via inactivation of nuclear factor κB signaling.
Tian K, Liu Z, Wang J, Xu S, You T, Liu P. Tian K, et al. Among authors: liu z, liu p. Transl Res. 2015 Mar;165(3):374-86. doi: 10.1016/j.trsl.2014.08.008. Epub 2014 Nov 13. Transl Res. 2015. PMID: 25475987
Effectiveness of combination therapy of atorvastatin and non lipid-modifying tanshinone IIA from Danshen in a mouse model of atherosclerosis.
Xu S, Liu Z, Huang Y, Chen J, Chen S, Shen X, Huang H, Liu P. Xu S, et al. Among authors: liu z, liu p. Int J Cardiol. 2014 Jul 1;174(3):878-80. doi: 10.1016/j.ijcard.2014.04.226. Epub 2014 Apr 26. Int J Cardiol. 2014. PMID: 24814901 No abstract available.
Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1.
Liu Z, Wang J, Huang E, Gao S, Li H, Lu J, Tian K, Little PJ, Shen X, Xu S, Liu P. Liu Z, et al. Among authors: liu p. J Lipid Res. 2014 Feb;55(2):201-13. doi: 10.1194/jlr.M040394. Epub 2013 Dec 3. J Lipid Res. 2014. PMID: 24302760 Free PMC article.
HDL cholesterol in cardiovascular diseases: the good, the bad, and the ugly?
Xu S, Liu Z, Liu P. Xu S, et al. Among authors: liu z, liu p. Int J Cardiol. 2013 Oct 9;168(4):3157-9. doi: 10.1016/j.ijcard.2013.07.210. Epub 2013 Jul 30. Int J Cardiol. 2013. PMID: 23962777
Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
Zou J, Le K, Xu S, Chen J, Liu Z, Chao X, Geng B, Luo J, Zeng S, Ye J, Liu P. Zou J, et al. Among authors: liu z, liu p. Mol Cell Endocrinol. 2013 May 6;370(1-2):103-12. doi: 10.1016/j.mce.2013.03.006. Epub 2013 Mar 18. Mol Cell Endocrinol. 2013. PMID: 23518069
Cardiovascular actions and therapeutic potential of tanshinone IIA.
Gao S, Liu Z, Li H, Little PJ, Liu P, Xu S. Gao S, et al. Among authors: liu z, liu p. Atherosclerosis. 2012 Jan;220(1):3-10. doi: 10.1016/j.atherosclerosis.2011.06.041. Epub 2011 Jun 30. Atherosclerosis. 2012. PMID: 21774934 Review.
49,272 results
Jump to page
Feedback